mRNA therapeutics
Optimising and scaling mRNA process development for next-generation medicines.
Get to market faster with CPI
At CPI, we accelerate the development and scale-up of mRNA-based therapeutics, providing the expertise, infrastructure, and process optimisation needed to support pre-clinical research and clinical manufacturing.
Our advanced bioprocessing, formulation, and lipid nanoparticle (LNP) encapsulation capabilities enable the efficient production of high-quality mRNA, ensuring stability, purity, and scalability. Whether optimising RNA synthesis, purification, or delivery technologies, we provide the tools and expertise to de-risk your journey from discovery to clinical trials.
mRNA therapeutics
Optimising and scaling mRNA process development for next-generation medicines.
Get to market faster with CPI
At CPI, we accelerate the development and scale-up of mRNA-based therapeutics, providing the expertise, infrastructure, and process optimisation needed to support pre-clinical research and clinical manufacturing.
Our advanced bioprocessing, formulation, and lipid nanoparticle (LNP) encapsulation capabilities enable the efficient production of high-quality mRNA, ensuring stability, purity, and scalability. Whether optimising RNA synthesis, purification, or delivery technologies, we provide the tools and expertise to de-risk your journey from discovery to clinical trials.
mRNA therapeutics
Optimising and scaling mRNA process development for next-generation medicines.
Get to market faster with CPI
At CPI, we accelerate the development and scale-up of mRNA-based therapeutics, providing the expertise, infrastructure, and process optimisation needed to support pre-clinical research and clinical manufacturing.
Our advanced bioprocessing, formulation, and lipid nanoparticle (LNP) encapsulation capabilities enable the efficient production of high-quality mRNA, ensuring stability, purity, and scalability. Whether optimising RNA synthesis, purification, or delivery technologies, we provide the tools and expertise to de-risk your journey from discovery to clinical trials.
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
mRNA process development and scale-up
Accelerate your mRNA therapeutics pipeline with our advanced development and scale-up solutions:
Enzymatic synthesis of natural and modified mRNA.
Advanced capping technologies for improved stability.
Optimised purification via filtration and chromatography.
High-throughput bioreactor systems for process scalability.
RNA characterisation and integrity assessments.
These capabilities ensure efficient, high-yield mRNA production for preclinical and clinical applications.
Lipid nanoparticle (LNP) encapsulation and downstream processing
Enhance mRNA delivery and stability with our LNP formulation and processing expertise:
Formulation development for encapsulated mRNA with cryoprotectants.
Freeze-drying to improve product stability.
Microfluidic and T-Piece systems for precise mixing technologies.
GMP-compliant downstream processing, including TFF, dialysis, and filtration.
Particle characterisation and stability testing under varied conditions.
These capabilities support mRNA vaccine and therapeutic development, ensuring effective drug delivery.
mRNA supply for toxicology and clinical studies
Secure high-quality mRNA materials for preclinical and early-stage clinical research:
Production scales from 1 mg to 20 g for preclinical applications.
GMP and non-GMP synthesis for toxicology and Phase 1 clinical studies.
Integration with supply chain partners for seamless drug product manufacturing.
Quality management services, including ‘Qualified Person’ product release.
We ensure your mRNA-LNP formulations meet the highest quality and regulatory standards.
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
mRNA process development and scale-up
Accelerate your mRNA therapeutics pipeline with our advanced development and scale-up solutions:
Enzymatic synthesis of natural and modified mRNA.
Advanced capping technologies for improved stability.
Optimised purification via filtration and chromatography.
High-throughput bioreactor systems for process scalability.
RNA characterisation and integrity assessments.
These capabilities ensure efficient, high-yield mRNA production for preclinical and clinical applications.
Lipid nanoparticle (LNP) encapsulation and downstream processing
Enhance mRNA delivery and stability with our LNP formulation and processing expertise:
Formulation development for encapsulated mRNA with cryoprotectants.
Freeze-drying to improve product stability.
Microfluidic and T-Piece systems for precise mixing technologies.
GMP-compliant downstream processing, including TFF, dialysis, and filtration.
Particle characterisation and stability testing under varied conditions.
These capabilities support mRNA vaccine and therapeutic development, ensuring effective drug delivery.
mRNA supply for toxicology and clinical studies
Secure high-quality mRNA materials for preclinical and early-stage clinical research:
Production scales from 1 mg to 20 g for preclinical applications.
GMP and non-GMP synthesis for toxicology and Phase 1 clinical studies.
Integration with supply chain partners for seamless drug product manufacturing.
Quality management services, including ‘Qualified Person’ product release.
We ensure your mRNA-LNP formulations meet the highest quality and regulatory standards.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
mRNA process development and scale-up
Accelerate your mRNA therapeutics pipeline with our advanced development and scale-up solutions:
Enzymatic synthesis of natural and modified mRNA.
Advanced capping technologies for improved stability.
Optimised purification via filtration and chromatography.
High-throughput bioreactor systems for process scalability.
RNA characterisation and integrity assessments.
These capabilities ensure efficient, high-yield mRNA production for preclinical and clinical applications.
Lipid nanoparticle (LNP) encapsulation and downstream processing
Enhance mRNA delivery and stability with our LNP formulation and processing expertise:
Formulation development for encapsulated mRNA with cryoprotectants.
Freeze-drying to improve product stability.
Microfluidic and T-Piece systems for precise mixing technologies.
GMP-compliant downstream processing, including TFF, dialysis, and filtration.
Particle characterisation and stability testing under varied conditions.
These capabilities support mRNA vaccine and therapeutic development, ensuring effective drug delivery.
mRNA supply for toxicology and clinical studies
Secure high-quality mRNA materials for preclinical and early-stage clinical research:
Production scales from 1 mg to 20 g for preclinical applications.
GMP and non-GMP synthesis for toxicology and Phase 1 clinical studies.
Integration with supply chain partners for seamless drug product manufacturing.
Quality management services, including ‘Qualified Person’ product release.
We ensure your mRNA-LNP formulations meet the highest quality and regulatory standards.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
What we offer
Whether you need technical expertise, lab-based development, process optimisation, or regulatory guidance, our tailored approach ensures you have the right support at every stage.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
mRNA process development and scale-up
Accelerate your mRNA therapeutics pipeline with our advanced development and scale-up solutions:
Enzymatic synthesis of natural and modified mRNA.
Advanced capping technologies for improved stability.
Optimised purification via filtration and chromatography.
High-throughput bioreactor systems for process scalability.
RNA characterisation and integrity assessments.
These capabilities ensure efficient, high-yield mRNA production for preclinical and clinical applications.
Lipid nanoparticle (LNP) encapsulation and downstream processing
Enhance mRNA delivery and stability with our LNP formulation and processing expertise:
Formulation development for encapsulated mRNA with cryoprotectants.
Freeze-drying to improve product stability.
Microfluidic and T-Piece systems for precise mixing technologies.
GMP-compliant downstream processing, including TFF, dialysis, and filtration.
Particle characterisation and stability testing under varied conditions.
These capabilities support mRNA vaccine and therapeutic development, ensuring effective drug delivery.
mRNA supply for toxicology and clinical studies
Secure high-quality mRNA materials for preclinical and early-stage clinical research:
Production scales from 1 mg to 20 g for preclinical applications.
GMP and non-GMP synthesis for toxicology and Phase 1 clinical studies.
Integration with supply chain partners for seamless drug product manufacturing.
Quality management services, including ‘Qualified Person’ product release.
We ensure your mRNA-LNP formulations meet the highest quality and regulatory standards.
mRNA therapeutics
applications
We enable innovation across a wide range of mRNA applications.
mRNA vaccines.
mRNA-based therapeutics.
LNP delivery systems.
Gene editing tools.
Protein replacement therapies.
Regenerative medicine.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Demonstrate the benefits of your mRNA innovation
Leverage our expertise, tools, and infrastructure to accelerate early-stage development with:
Rapid, cost-effective mRNA process development to support funding and investment.
Validation of mRNA-LNP formulations in industry-relevant settings.
Optimisation of mRNA therapies for enhanced efficacy and stability.
Prove manufacturability and scalability
Ensure your mRNA therapies are scalable and reproducible with our advanced processing expertise. With CPI, you can access:
Early-stage manufacturability assessments to evaluate production feasibility.
Process optimisation for cost-effective, high-yield mRNA synthesis.
Scalable production methods supporting preclinical and clinical development.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure investment and commercial partnerships. We support with:
Commercial feasibility assessments for mRNA-based therapeutics.
Validation of scale-up processes to secure funding or licensing deals.
Transitioning from preclinical development to commercial production.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-compliant mRNA production facilities.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to mitigate risk.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We help you to:
Access world-class mRNA manufacturing partners.
Build robust supply chains for drug product production.
Collaborate on industry-wide mRNA innovation challenges.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
Demonstrate the benefits of your mRNA innovation
Leverage our expertise, tools, and infrastructure to accelerate early-stage development with:
Rapid, cost-effective mRNA process development to support funding and investment.
Validation of mRNA-LNP formulations in industry-relevant settings.
Optimisation of mRNA therapies for enhanced efficacy and stability.
Prove manufacturability and scalability
Ensure your mRNA therapies are scalable and reproducible with our advanced processing expertise. With CPI, you can access:
Early-stage manufacturability assessments to evaluate production feasibility.
Process optimisation for cost-effective, high-yield mRNA synthesis.
Scalable production methods supporting preclinical and clinical development.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure investment and commercial partnerships. We support with:
Commercial feasibility assessments for mRNA-based therapeutics.
Validation of scale-up processes to secure funding or licensing deals.
Transitioning from preclinical development to commercial production.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-compliant mRNA production facilities.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to mitigate risk.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We help you to:
Access world-class mRNA manufacturing partners.
Build robust supply chains for drug product production.
Collaborate on industry-wide mRNA innovation challenges.
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Demonstrate the benefits of your mRNA innovation
Leverage our expertise, tools, and infrastructure to accelerate early-stage development with:
Rapid, cost-effective mRNA process development to support funding and investment.
Validation of mRNA-LNP formulations in industry-relevant settings.
Optimisation of mRNA therapies for enhanced efficacy and stability.
Prove manufacturability and scalability
Ensure your mRNA therapies are scalable and reproducible with our advanced processing expertise. With CPI, you can access:
Early-stage manufacturability assessments to evaluate production feasibility.
Process optimisation for cost-effective, high-yield mRNA synthesis.
Scalable production methods supporting preclinical and clinical development.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure investment and commercial partnerships. We support with:
Commercial feasibility assessments for mRNA-based therapeutics.
Validation of scale-up processes to secure funding or licensing deals.
Transitioning from preclinical development to commercial production.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-compliant mRNA production facilities.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to mitigate risk.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We help you to:
Access world-class mRNA manufacturing partners.
Build robust supply chains for drug product production.
Collaborate on industry-wide mRNA innovation challenges.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
How we support you
From discovery to commercialisation, we enable scalable, cost-effective, and regulatory-compliant pharmaceutical innovations.
Demonstrate the benefits of your mRNA innovation
Leverage our expertise, tools, and infrastructure to accelerate early-stage development with:
Rapid, cost-effective mRNA process development to support funding and investment.
Validation of mRNA-LNP formulations in industry-relevant settings.
Optimisation of mRNA therapies for enhanced efficacy and stability.
Prove manufacturability and scalability
Ensure your mRNA therapies are scalable and reproducible with our advanced processing expertise. With CPI, you can access:
Early-stage manufacturability assessments to evaluate production feasibility.
Process optimisation for cost-effective, high-yield mRNA synthesis.
Scalable production methods supporting preclinical and clinical development.
Assess and demonstrate commercial viability
We provide data-driven insights and process validation to secure investment and commercial partnerships. We support with:
Commercial feasibility assessments for mRNA-based therapeutics.
Validation of scale-up processes to secure funding or licensing deals.
Transitioning from preclinical development to commercial production.
Streamline regulatory compliance
We help to de-risk regulatory pathways, ensuring compliance with global standards. Our experts provide:
GMP-compliant mRNA production facilities.
Regulatory support for EMA, FDA, and MHRA approvals.
Quality assurance and documentation to mitigate risk.
Secure strategic partnerships
As a trusted UK Government partner, we have built a broad network across global leaders, emerging companies, large corporates, healthcare, and academia. We help you to:
Access world-class mRNA manufacturing partners.
Build robust supply chains for drug product production.
Collaborate on industry-wide mRNA innovation challenges.
Can't find what you're looking for?
With over 500 experts we are here to help.
500+
We are over 500 world-class innovation experts, scientists and engineers.
We are over 500 world-class innovation experts, scientists and engineers.
We are over 500 world-class innovation experts, scientists and engineers.
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
£3 billion of private investment unlocked
R&D projects delivered
Years of experience
Business collaborations
m² of facilities
Over £220m of innovation assets
Trusted by leading organisations
,
Why choose CPI?
Work with us to defer capital and workforce investments until your product or process is proven at scale.
mRNA expertise
Proven success in process development and formulation.
Industry-leading infrastructure
We support full-scale mRNA and lipid nanoparticle manufacturing, with our RNA and Intracellular Drug Delivery Centres of Excellence.
Collaborative approach
We connect you with industry partners, funding opportunities, and regulatory insights to de-risk your journey.
End-to-end support
From early-stage development to clinical trials.
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Philip Probert
mRNA therapeutics
Business Development
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Philip Probert
mRNA therapeutics
Business Development
Get in touch
Let's innovate together
At CPI, we understand that every innovation, manufacturing process, and application is unique. Our flexible engagement model builds custom projects around your goals.
Philip Probert
mRNA therapeutics
Business Development
